G
93.55
7.90 (9.22%)
| Previous Close | 85.65 |
| Open | 86.95 |
| Volume | 1,988,963 |
| Avg. Volume (3M) | 1,048,453 |
| Market Cap | 3,646,787,072 |
| Price / Sales | 23.07 |
| Price / Book | 1.63 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -482.59% |
| Diluted EPS (TTM) | -59.59 |
| Quarterly Revenue Growth (YOY) | 19.10% |
| Total Debt/Equity (MRQ) | 2.67% |
| Current Ratio (MRQ) | 9.70 |
| Operating Cash Flow (TTM) | -464.88 M |
| Levered Free Cash Flow (TTM) | -236.88 M |
| Return on Assets (TTM) | -11.98% |
| Return on Equity (TTM) | -62.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | GRAIL, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 14.18% |
| % Held by Institutions | 66.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Canaccord Genuity, 12.24%) | Buy |
| Median | 102.50 (9.57%) | |
| Low | 100.00 (Guggenheim, 6.90%) | Buy |
| Average | 102.50 (9.57%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 84.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 17 Nov 2025 | 105.00 (12.24%) | Buy | 84.94 |
| 22 Oct 2025 | 85.00 (-9.14%) | Buy | 79.76 | |
| Guggenheim | 12 Nov 2025 | 100.00 (6.89%) | Buy | 84.77 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |